Original Article

Psychometric validation of the Chinese version of the M. D. Anderson Symptom Inventory—Head and Neck Module in patients with nasopharyngeal carcinoma

Wenli Xiaoa, Carmen W.H. Chanc, Xin Shelley Wanga, Jinnan Xiaod, Marques S.N. Ngb,*,1

a School of Nursing, Guangzhou University of Chinese Medicine, Guangzhou, China
b The Nethersole School of Nursing, The Chinese University of Hong Kong, Hong Kong SAR, China
c Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
d Xiangya School of Nursing, Central South University, Changsha, China

ARTICLE INFO

Keywords:
Nasopharyngeal carcinoma
Head and neck cancer
Symptom burden
MDASI-HN
Validation

ABSTRACT

Objective: The Chinese version of the M. D. Anderson Symptom Inventory—Head and Neck Module (MDASI-HN-C) has been linguistically validated. However, its psychometric properties have not been established yet. The purpose of the study was to psychometrically validate the MDASI-HN-C in patients with nasopharyngeal carcinoma (NPC).

Methods: 130 Chinese NPC patients who were undergoing radiotherapy (RT) participated in this cross-sectional study. The content, convergent, and construct validity of the MDASI-HN-C were examined. The reliability of the instrument was tested by examining the internal consistency and test–retest reliability.

Results: Cronbach's α coefficients ranged from 0.85 to 0.91 for the three subscales of the MDASI-HN-C. The 3-day test–retest reliability was acceptable with intraclass correlation coefficients (ICC) ranged from 0.52 to 0.71. The scale content validity index (S-CVI) was satisfactory (0.97). Subscale scores of the MDASI-HN-C were negatively correlated with the total score of the Chinese version of the Functional Assessment of Cancer Therapy—Head and Neck Scale (FACT-H&N-C) as hypothesized (r = −0.484 to −0.563, all P < 0.01). Exploratory factor analysis (EFA) revealed two factors for the 13 core and another two for the nine HNC-specific items. Only one factor was generated for the six interference items.

Conclusions: The MDASI-HN-C shows desirable psychometric properties for evaluating symptom burden in NPC patients, which can be used in both clinical and research contexts.

Introduction

Nasopharyngeal carcinoma (NPC) is relatively uncommon with an incidence of 133,354 new cases worldwide, accounting for 0.7% of all sites in 2020.1 However, it is endemic in eastern and south-eastern Asia, and 46.8% of new cases in the world occurs in China.1,2 Radiotherapy (RT) alone or combined with chemotherapy (CTX) are the main treatments, and the five-year overall survival rate of NPC patients can be as high as 70%–80%.3,5 However, symptoms associated with the disease and treatment such as taste change, xerostomia, sticky saliva, sore throat, and anorexia are still major problems, which may lead to treatment interruption and declined emotional well-being, functional performance, and quality of life (QOL).3–8 In addition, these symptoms can form clusters that increase patients’ symptom burden.9–12 Timely identification and monitoring of symptoms is critical to symptom management. Compared with assessing symptoms by clinicians, because using patient reported outcome instruments can elicit the patient experience directly, it is superior in both clinical and research contexts.13 Therefore, a psychometrically sound instrument is warranted to evaluate symptoms experienced by NPC patients.

There is currently no NPC-specific symptom assessment instrument. Given that NPC is one kind of head and neck cancers (HNCs), we looked for HNC-specific instruments instead to assess symptoms experienced by NPC patients. However, most of these HNC-specific instruments were designed to measure QOL, such as the European Organization for Research and Treatment of Cancer (EORTC) QOL Core Questionnaire.
The Head and Neck Cancer Inventory (HNCI). These QOL instruments often omit specific symptoms and the distress they cause.15

The Vanderbilt Head and Neck Symptom Survey (VHNSS) and the Head and Neck Symptom Checklist (HNSSC) are instruments that focus on HNC-specific symptoms.19,20 However, the VHNSS and the HNSSC were designed to assess only oral health outcomes and nutrition impact symptoms, respectively. Another two instruments found were the Head and Neck Distress Scale (HNDS) and the M. D. Anderson Symptom Inventory—Head and Neck Module (MDASI-HN),18,21 which were both developed by the University of Texas M. D. Anderson Cancer Center in 2006 and 2007, respectively. However, the HNDS has a long recall period of one month that affects its practicality. Unlike the HNSSC and HNDS, the MDASI-HN is more comprehensive and assesses symptoms occurring in the last 24 h.

The English version of the MDASI-HN was developed in two steps. First, Cleeland and colleagues developed the original MDASI with two subscales, including 13 core items for assessing the severity of generic cancer-related symptoms and six interference items for evaluating the influence of symptoms on daily living activities. The 13 core items measure two underlying constructs: (1) a factor comprising pain, fatigue, disturbed sleep, feeling of being distressed, shortness of breath, feeling drowsy, having a dry mouth, feeling sad, problem with remembering things, and numbness or tingling; and (2) a factor comprising nausea and vomiting. The symptom lack of appetite loads on both of these constructs.22 The MDASI has been widely used and validated in various languages, including Chinese.23 Second, another subscale containing nine HNC-specific items for measuring the severity of symptoms associated with HNC was developed. These three subscales formed the 28-item MDASI-HN. The nine HNC-specific items measure two underlying constructs: (1) a factor comprising mouth/throat sores, problem with tasting food, constipation, problem with teeth or gums, and skin pain/burning/rash; and (2) a factor comprising difficulty with voice/speech, choking/coughing, difficulty swallowing/chewing, and problem with mucus.18 Because of its comprehensiveness, ease of understanding, promptness, and brevity, the MDASI-HN is considered as the most appropriate instrument to assess symptom burden in NPC patients.18,24

To date, the Filipino, Spanish, and Italian versions of MDASI-HN has been psychometrically validated.25–27 The Chinese version of the MDASI-HN (MDASI-HN-C) (Appendix 1) has been translated by the M. D. Anderson Cancer Center and demonstrated good adaptation to the Chinese context. However, while its psychometric properties have not been evaluated, its routine use in clinical and research settings in China is hindered. Therefore, the aim of the study was to psychometrically validate the MDASI-HN-C by examining its reliability and validity in patients with NPC.

Methods

Study design and patient recruitment

This study adopted a cross-sectional design. It was conducted in the NPC department of Sun Yat-sen University Cancer Center, Guangzhou, China. The inclusion criteria were: (1) first-treated Chinese NPC patients; (2) undergoing RT at the time; (3) 18 years old or above; and (4) able to communicate in Mandarin or Cantonese. Patients who had been diagnosed with psychiatric morbidity or other types of cancer were excluded.

Instruments

Sociodemographic and clinical data questionnaires were constructed to collect information such as gender, age, educational level, marital status, occupational status, weight loss during treatment, stage of disease, number of times RT received, and type of CTX. The data were reported by the participants or retrieved from the medical records.

The MDASI-HN-C contains 28 items in three subscales, namely: core symptoms (13 items), HNC-specific symptoms (9 items) and symptom interference (6 items). All items are rated based on a 0–10 scale to measure symptom severity or interference over the last 24 h, with 0 indicating “not present” or “did not interfere” and 10 “as bad as you can imagine” or “interfered completely.” It takes approximately 5 min to complete the questionnaire. The Cronbach’s α coefficients range from 0.83 to 0.92 for the three subscales.

The 39-item FACT-H&N (version 4) was used to establish the construct validity of the MDASI-HN-C. The English version of the FACT-H&N is a validated HNC-specific QOL instrument consisting of five domains,15,16 namely: physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items) and HNC-specific concerns (12 items) in the past seven days based on a 0–4 scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The Chinese version of the FACT-H&N (FACT-H&N-C) had been used on NPC patients with acceptable internal consistency (Cronbach’s α = 0.75).28

Data collection

After obtaining ethical approval, eligible patients were approached consecutively. A signed information sheet and consent form was obtained from each participant. The whole questionnaire was completed mainly by patients themselves and the researcher was available if any assistance was needed. Based on the experience of previous studies,29–31 the MDASI-HN-C was administered again three days later with a convenient subsample to evaluate the test–retest reliability of the instrument. A total of 66 participants could be reached in wards by the researcher to complete the second questionnaire.

Data analysis

Descriptive statistics such as the mean, standard deviation (SD) and frequency (%) were used to describe the study sample. Inferential statistics such as the intraclass correlation, Pearson product–moment correlation, as well as confirmatory (CFA) and exploratory (EFA) factor analyses were used to evaluate the reliability and validity of the MDASI-HN-C. While the LISREL 8.8 (Scientific Software International Inc., Skokie, IL) was used to conduct the CFA, other statistical tests were conducted using SPSS 21.0 (IBM Corp., Armonk, NY). A P-value < 0.05 indicates statistically significant results.

Content validity was examined by calculating the content validity index (CVI) including item CVI (I-CVI) and scale CVI (S-CVI).32 An expert panel with expertise in NPC treatment and care, including two oncologists, two oncology nurses and one academic researcher, was established to evaluate the content validity of the MDASI-HN-C on a scale ranging from 1 to 4 (1 = not relevant; 2 = somewhat relevant; 3 = quite relevant; 4 = highly relevant). The I-CVI equals the number giving a rating of 3 or 4 divided by the number of raters, while the S-CVI is computed by averaging all I-CVIs. A minimum value of 0.8 for the I-CVI and 0.9 for the S-CVI are considered acceptable.32

To examine the convergent validity, the Pearson product–moment correlation was used to determine the correlation of the MDASI-HN-C and the FACT-H&N-C based on the hypothesis that the symptom burden and QOL are negatively correlated. A correlation coefficient between 0.1 and 0.29, 0.3 and 0.49, and 0.5 and 1.0 represents small, medium, and large effect size, respectively.33

CFA was conducted based on the 2-factor structure of core symptoms and the 2-factor structure of HNC-specific symptoms suggested by the instrument developers.18,22 The CFA was conducted in three steps: (1) a confirmatory factor analysis (CFA); (2) exploratory factor analysis (EFA); and (3) model optimization in CFA. The EFA was used to determine model fitness: degree of freedom ratio (χ^2/df ≤ 3), root-mean-square error of approximation (RMSEA ≤ 0.08), standardized root-mean-square residual (SRMR ≤ 0.1), adjusted goodness-of-fit index (AGFI ≥ 0.9), comparative fit index (CFI ≥ 0.9) and non-normed fit index (NNFI ≥ 0.9).
As the data did not fit the structures well, EFA was then performed using principle axis factor analysis with oblimin rotation to examine the factor structures of the 13 core and nine HNC-specific items separately. Since the instrument developers did not examine the factor structure of the six interference items, only EFA was conducted for this subscale. Intraclass correlation coefficient (ICC) was used to evaluate the 3-day test–retest reliability. An ICC below 0.4 represents poor reliability, between 0.4 and 0.75 represents fair to good reliability, and above 0.75 represents excellent reliability.

Ethical considerations

The study was approved by the Survey and Behavioural Research Ethics Committee of the Chinese University of Hong Kong.

Results

Characteristics of participants

A total of 130 patients with NPC participated in the study. The sociodemographic and clinical characteristics of the sample are presented in Table 1. The mean ± SD age was 43.22 ± 9.75 years (range 18–65). Most of the participants were male (72.3%), married (91.5%), employed (59.2%) and had received junior high or above levels of education (86.9%). The mean ± SD weight loss was 5.13 ± 3.58 kg. 87.7% of the participants were in a stage III or IV of the disease according to the 7th edition of the TNM classification. The average number of RT treatments received by participants were 21.48 ± 4.80 (mean ± SD) and majority of them (97.7%) received the treatment of CTX. Detailed information on characteristics of this sample has also been reported in our previous publication.

Validity of the MDASI-HN-C

The I-CVI of one item (item 6: shortness of breath) was computed as 0.50. Another two items (item 7: problem with remembering things and item 13: numbness or tingling) had an I-CVI of 0.80. The I-CVI for the remaining 25 items was 1.00. The S-CVI of the MDASI-HN-C was 0.97, indicating satisfactory content validity.

The three subscale scores of the MDASI-HN-C correlated negatively with the total score of the FACT-H&N-C (rcore = −0.496, rHNC-specific = −0.484, rifference = −0.563; all P < 0.01) and three domain scores, namely: physical (rcore = −0.679, rHNC-specific = −0.596, rifference = −0.723; all P < 0.01), emotional (rcore = −0.373, rHNC-specific = −0.321, rifference = −0.466; all P < 0.01) and HNC-specific (rcore = −0.356, rHNC-specific = −0.453, rifference = −0.359; all P < 0.01), with medium to large effect size. The functional domain of the FACT-H&N-C were negatively correlated with the core and interference subscale scores of the MDASI-HN-C only with small effect size (rcore = −0.202, P < 0.05; rifference = −0.296, P < 0.01). No statistically significant correlations were found between any of the three subscale scores of the MDASI-HN-C and the social/family domain. Details of the associations between the MDASI-HN-C and the FACT-H&N-C are provided in Table 2. The significant negative correlation coefficients indicated that more severe symptom burden was related to poorer QOL. This result shows the good convergent validity of the instrument.

The results of the CFA indicate that the 2-factor structure of the MDASI-HN-C core symptoms (χ² = 142.8, df = 63, P < 0.001; RMSEA = 0.101; SRMR = 0.064; CFI = 0.95; NNFI = 0.94; AGFI = 0.78) was not satisfactorily fitted by the data. Regarding the MDASI-HN-C HNC-specific symptoms, our data did not fit the 2-factor structure (χ² = 72.5, df = 26, P < 0.001; RMSEA = 0.118; SRMR = 0.067; CFI = 0.94; NNFI = 0.92; AGFI = 0.81). In the EFA, we identified two factors for both two subscales but with different constituting items comparing with the findings of the instrument developers. Specifically, for the 13 core items, principle axis factor analysis revealed two factors, explaining 47.25% and 8.79% of the variance respectively. Factor 1 comprised 11 items (general symptoms): feeling drowsy, shortness of breath, feeling of being distressed, feeling sad, numbness or tingling, disturbed sleep, fatigue, problem with remembering things, pain, lack of appetite and having a dry mouth. Factor 2 consisted of two items (gastrointestinal symptoms): nausea and vomiting. For the nine HNC-specific items, another two factors, explaining 47.65% and 11.48% of the variance respectively. Factor 3 covered six items (nutrition impact symptoms): problem with mucus, mouth/throat sores, difficulty swallowing/chewing, problem with tasting food, problem with teeth or gums and constipation. Factor 4 covered three items (social interaction impact symptoms): choking/coughing, difficulty with voice/speech and skin pain/burning/itching. The three-day test–retest reliability of the MDASI-HN-C was also acceptable, with ICC ranging from 0.48 to 0.71, which represented fair to good reliability (Table 4).

Discussion

The MDASI has been widely used to assess symptom burden in various cancer patients and the MDASI-HN was developed and validated

Table 1

Sociodemographic and clinical characteristics of participants (n = 130).

| Characteristics                      | Mean (SD) | n (%)  |
|--------------------------------------|-----------|--------|
| Gender                               |           |        |
| Male                                 | 94 (72.3) |        |
| Female                               | 36 (27.7) |        |
| Age (years)                          | 43.22 (9.75) |    |
| Educational level                    |           |        |
| Primary                              | 17 (13.1) |        |
| Junior high                          | 39 (30.0) |        |
| Senior high                          | 39 (30.0) |        |
| Tertiary or above                    | 35 (26.9) |        |
| Marital status                       |           |        |
| Single or widowed                    | 11 (8.5)  |        |
| Married                              | 119 (91.5)|        |
| Occupational status                  |           |        |
| Unemployed                           | 53 (40.8) |        |
| Employed                             | 77 (59.2) |        |
| Weight loss (kg)                     | 5.13 (3.58)|        |
| Clinical stage                       |           |        |
| I                                    | 1 (0.8)   |        |
| II                                   | 15 (11.5) |        |
| III                                  | 74 (56.9) |        |
| IV                                   | 40 (30.8) |        |
| Number of times of RT                | 21.48 (4.80) |    |
| Type of CTX                          |           |        |
| No CTX                               | 3 (2.3)   |        |
| Neoadjuvant                          | 5 (3.8)   |        |
| Concurrent                           | 58 (44.6) |        |
| Neoadjuvant + concurrent             | 64 (49.2) |        |

Abbreviations: CTX, Chemotherapy; RT, Radiotherapy; SD, Standard deviation.
Table 2
Correlation between the MDASI-HN-C and the FACT-H&N-C.

| MDASI-HN-C domains | Correlation with FACT-H&N-C (r) |
|--------------------|--------------------------------|
|                    | Physical | Social/family | Emotional | Functional | HNC-specific | Total |
| Core               | -0.679** | 0.028         | -0.372** | -0.202**  | -0.356**    | -0.496** |
| HNC-specific       | -0.596** | -0.036        | -0.321** | -0.150**  | -0.453**    | -0.484** |
| Interference       | -0.723** | 0.052         | -0.466** | -0.296**  | -0.359**    | -0.563** |

Abbreviations: FACT-H&N-C, Chinese version of the Functional Assessment of Cancer Therapy—Head and Neck Scale; HNC, Head and neck cancer; M, Mean; MDASI-HN-C, Chinese version of the M. D. Anderson Symptom Inventory-Head and Neck Module; SD, Standard deviation.

*P < 0.05; **P < 0.01.

Table 3
Exploratory factor analysis of the MDASI-HN-C.

| MDASI-HN-C domains | Factor loadings |
|--------------------|----------------|
|                    | Factor | Factor | Factor | Factor | Factor |
|                    | 1      | 2      | 3      | 4      | 5      |
| Core               |        |        |        |        |        |
| Feeling drowsy     | 0.833  | 0.084  |        |        |        |
| Shortness of breath| 0.799  | 0.104  |        |        |        |
| Feeling of being distressed | 0.797 | 0.052  |        |        |        |
| Feeling sad        | 0.714  | 0.059  |        |        |        |
| Numberness or tingling | 0.596 | 0.018  |        |        |        |
| Disturbed sleep    | 0.530  | -0.163 |        |        |        |
| Fatigue            | 0.527  | -0.227 |        |        |        |
| Problem with remembering things | 0.510 | -0.106 |        |        |        |
| Pain               | 0.490  | -0.072 |        |        |        |
| Lack of appetite   | 0.479  | -0.280 |        |        |        |
| Having a dry mouth | 0.322  | -0.276 |        |        |        |
| Nausea             | 0.099  | -0.925 |        |        |        |
| Vomiting           | 0.057  | -0.853 |        |        |        |
| HNC-specific       |        |        |        |        |        |
| Problem with mucus |        |        | 0.878  | -0.025 |        |
| Mouth/throat sores |        |        | 0.694  | 0.162  |        |
| Difficulty swallowing/chewing | 0.576 | 0.239  |        |        |        |
| Problem with tasting food | 0.571 | -0.109 |        |        |        |
| Problem with teeth or gums | 0.436 | 0.148  |        |        |        |
| Constipation       | 0.374  | 0.260  |        |        |        |
| Choking/coughing   |        | -0.023 | 0.750  |        |        |
| Difficulty with voice/speech | 0.073 | 0.736  |        |        |        |
| Skin pain/burning/rash | 0.033 | 0.551  |        |        |        |
| Interference       |        |        |        |        |        |
| Enjoyment of life  |        |        |        |        | 0.820  |
| General activity   |        |        |        |        | 0.818  |
| Mood               |        |        |        |        | 0.803  |
| Work               |        |        |        |        | 0.762  |
| Walking            |        |        |        |        | 0.668  |
| Relations with other people | 0.625 |        |        |        |        |

Abbreviations: HNC, Head and neck cancer; MDASI-HN-C, Chinese version of the M. D. Anderson Symptom Inventory—Head and Neck Module. Major loadings (> 0.3 or < -0.3) in each factor are bolded.

later especially for HNC patients. As an instrument designed to measure symptoms and with advantages of comprehensiveness, ease of understanding, promptness, and brevity, it is considered to be the most appropriate instrument for assessing symptom burden in NPC patients. Although the MDASI-HN has been translated into Chinese and validated linguistically, its psychometric properties have not previously been examined. Therefore, this study psychometrically validated the MDASI-HN-C in Chinese NPC patients who were undergoing RT.

Except for item 6 “shortness of breath,” the I-CVI of all other items was above the suggested satisfactory value of 0.8. Two experts gave item 6 a rating of 2, indicating that the item is “somewhat relevant” to NPC patients. Although they pointed out that the prevalence of “shortness of breath” in NPC patients during treatment is not high, they suggested retaining this item as it does occur in a certain number of NPC patients. Therefore, we decided to keep the item 6 in the instrument to be further validated by patients.

Negative associations were found between the symptom burden and the total score of QOL, which was consistent with the findings from the validation studies of other versions. For the domains of QOL, all subscale scores of the MDASI-HN-C were significantly correlated with them, except for the social/family and functional domains. No statistically significant correlations were found between the MDASI-HN-C and the social/family domain, which might be explained by the relatively strong and stable family support in the context of Chinese culture. In addition, there was no statistically significant correlation between the HNC-specific subscale of the MDASI-HN-C and the functional domain, which might attribute to the general functions the domain mainly measures, such as work, sleep, and life satisfaction.

Factor analyses were performed to examine the internal structure of symptoms in the MDASI-HN-C. The researcher conducted CFA and EFA for the two subscales separately in order to follow the strategy adopted by the instrument developers, as well as for empirical reasons. Two factors were identified when examining the internal structure of the 13 core symptoms. This result was in line with some previous studies. Similar to the original English and translated Spanish versions, the nine HNC-specific symptoms generated two factors. However, items within each factor among these three language versions were not identical, which may be caused by different populations included in these studies.

The MDASI-HN-C demonstrated satisfactory internal consistency with high Cronbach’s α coefficients, which was consistent with the original, Filipino and Spanish versions of the instrument. The internal consistency was further supported by the item-to-total correlation lying within a range of 0.40–0.82. As for test–retest reliability, the ICC for the three subscales and their underlying constructs was only moderately high. One possible explanation is that patients’ symptoms change from day to day. In fact, the MDASI-HN-C was designed to measure symptoms on a daily basis (i.e., having a recall period of 24 h). Thus, the stability of the MDASI-HN-C was considered as acceptable.
By examining the content validity, convergent validity, construct validity, internal consistency, and test–retest reliability of the MDASI-HN-C in this study, its psychometric properties have been established. In addition to its strengths mentioned above, the validated MDASI-HN-C is the most suitable and practical instrument to assess symptom burden in Chinese NPC patients. Symptom management is always the key content for care of patients with cancer and symptom identification and monitoring are important links of management.41 The MDASI-HN-C cannot only assess the symptom severity but also the interference of symptom on daily living. Therefore, it can help clinicians to quickly and comprehensively assess patients’ symptom burden and monitor its longitudinal changes, so as to provide evidence for the formulation and evaluation of medical and nursing decisions. Besides, the MDASI-HN-C can also be used in a variety of research contexts regarding patient reported outcomes, such as research on symptom clusters in which multiple symptoms need to be evaluated simultaneously.

**Limitations**

Firstly, because this study was conducted in a single hospital in southern China, its generalizability may be affected. Secondly, symptoms were evaluated at a single time point in this cross-sectional study and the instrument’s sensitivity to changes is not known. Thirdly, except for the 22 symptoms contained in the instrument, we did not explore other symptoms. Therefore, there is a possibility that some NPC-specific symptoms, such as visual and auditory problems, are neglected.

**Conclusions**

To conclude, the MDASI-HN-C shows desirable psychometric properties for evaluating symptom burden in Chinese NPC patients. It can help clinicians to have a better understanding of the symptoms experienced by NPC patients. In addition, the MDASI-HN-C can be used in patient reported outcome research, especially in studies which assessments of multiple concurrent symptoms. Future multi-center, longitudinal studies that explore more NPC-specific symptoms for further validation of the instrument in patients with NPC are recommended.

**Acknowledgments**

We would like to express our heartfelt thanks to the hospital staff and the statistician for their contributions in data collection and analysis, respectively.

**Declaration of competing interest**

None declared.

**Funding**

Nil.

**Supplementary material**

To access the supplementary material accompanying this article, visit the online version of the *Asia-Pacific Journal of Oncology Nursing* at [http://doi.org/10.1016/j.apjon.2021.12.014](http://doi.org/10.1016/j.apjon.2021.12.014).

**References**

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin. 2021;71:209–249.
2. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Cancer. 2019;99:64–80.
3. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. J Chin Cancer. 2011;20:114–119.
4. Tsai WL, Chen CY, Huang HY, Liao KC, Fang PM. Prognostic value of quality of life measured after treatment on subsequent survival in patients with nasopharyngeal carcinoma. Qual Life Res. 2010;19:715–723.
5. Chen YP, Tsang NM, Tseng CK, Lin SY. Causes of interruption of radiotherapy in nasopharyngeal carcinoma patients in Taiwan. Jpn J Clin Oncol. 2009;39:236–244.
6. Fang FM, Chiu HC, Kuo WR, Wang CJ, Leung SW, Chen HC, et al. Health-related quality of life for nasopharyngeal carcinoma patients with cancer-free survival after treatment. Int J Radiat Oncol Biol Phys. 2002;53:959–968.
7. Liu H, Qin H. Study on correlation among illness uncertainty, symptoms distress and mood of hospitalized nasopharyngeal carcinoma patients during radiotherapy. Chin Nurs Res. 2011;25:2747–2749.
8. Wu Y, Hu WH, Xie YF, Ma J, Liu MZ, Cui NJ. Quality of life of nasopharyngeal carcinoma survivors in Mainland China. Qual Life Res. 2007;16:65–74.
9. Xiao W, Chan CHW, Fan Y, Leung DYP, Xia W, He Y, et al. Symptom clusters in patients with nasopharyngeal carcinoma during radiotherapy. Eur J Oncol Nurs. 2017;28:7–13.
10. Xiao W, Chan CHW, Xiao J, Lyu Q, Gong N, Wong CL, et al. Managing the nutrition impact symptom cluster in patients with nasopharyngeal carcinoma using an educational intervention program: a pilot study. Eur J Oncol Nurs. 2021;53:101986.
11. Xiao W, Chan CHW, Xiao J, Wong CL, Chow KM. Development of a nurse-led educational intervention program in managing the nutrition impact symptom cluster in patients with nasopharyngeal carcinoma following the Medical Research Council framework. Asia Pac J Oncol Nurs. 2021;8:653–661.
12. Xiao W, Chow KM, So YL, Leung SW, Chan CW. The effectiveness of psychoeducational intervention on managing symptom clusters in patients with cancer: a systematic review of randomized controlled trials. Cancer Nurs. 2016;39:279–291.
13. Gunn GB, Atalar B, Mendoza TR, Cleeck S, Selek U, Ozayar E, et al. Linguistic validation of the Turkish version of the M.D. Anderson Symptom Inventory - head and neck cancer module. Balkan Med J. 2016;33:339–343.
14. Bjordal K, de Greeff A, Fayers PM, Hammerlid E, van Pottelsbergh C, Curran D, et al. A 12-country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-HN35) in head and neck patients. Eur J Cancer. 2000;36:1796–1807.
15. List MA, D’Antonio LL, Cella DF, Siston A, Mumby P, Haraf D, et al. The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: a study of utility and validity. Cancer. 1996;77:2294–2301.
16. Ringborg J, Lockwood G, O’Sullivan B, Warde P, Bayley A, Cummings B, et al. Hyperfractionated, accelerated radiotherapy for locally advanced head and neck cancer: quality of life in a prospective phase I/II trial. Radiother Oncol. 2008;87:181–187.
17. Funk GF, Kannel LH, Christensen AJ, Moran PJ, Ricks J. Comprehensive head and neck oncology health status assessment. Head Neck. 2003;25:561–575.
18. Rosenhall DI, Mendoza TR, Chambers MS, Asper JA, Gning I, Kies MS, et al. Measuring head and neck cancer symptom burden: the development and validation of the M.D. Anderson symptom inventory, head and neck module. Head Neck. 2007;29:923–931.
19. Cooperstein E, Gilbert J, Epstein JB, Chalain AA, Weber RS, Weinstein GS, et al. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck. 2012;34:797–804.
20. Kubrak C, Olsin K, Baracos VE. The head and neck symptom checklist: an instrument to evaluate nutrition impact symptoms effect on energy intake and weight loss. Support Care Cancer. 2013;21:3127–3136.
21. Jones HA, Hershock D, Machaty M, Chalain AA, Weber RS, Weinstein GS, et al. Preliminary investigation of symptom distress in the head and neck patient population: validation of a measurement instrument. Am J Clin Oncol. 2006;29:158–162.
22. Cleeck S, Mendoza TR, Wang XS, Chou C, Harle MT, Morrissey M, et al. Assessing symptom distress in cancer patients: the M. D. Anderson Symptom Inventory. Cancer. 2000;89:1634–1646.
23. Wang XS, Wang Y, Guo H, Mendoza TR, Hao XS, Cleeck CS. Chinese version of the M. D. Anderson Symptom Inventory: validity and application of symptom measurement in cancer patients. Cancer. 2004;101:1890–1901.
24. Rosenhall DI, Mendoza TR, Chambers MS, Burkett VS, Garden AS, Hessell AC, et al. The M. D. Anderson Symptom Inventory-head and neck module, a patient reported outcome instrument, accurately predicts the severity of radiation-induced mucositis. Int J Radiat Oncol Biol Phys. 2008;72:1355–1361.
25. Bacorro WR, Sy Ortin TT, Suarez CG, Mendoza TR, Que JC. Validation of the MD Anderson Symptom Inventory-Head-and-Neck Filipino (MDASI-HN-F): clinical utility of symptom screening among patients with head-and-neck cancer. BMJ Support Palliat Care. 2017;7:140–149.
26. Sánchez D, Chala A, Alvarez A, Payam C, Mendoza T, Cleeck LA, et al. Psychometric validation of the M. D. Anderson symptom inventory-head and neck module in the Spanish language. J Pain Symptom Manag. 2016;51:1055–1061.
27. Vigano A, De Felice F, Iacovielli NA, Alterio D, Facchinetti N, Oneta O, et al. M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian
language psychometric validation in head and neck cancer patients treated with radiotherapy ± systemic therapy - a study of the Italian Association of Radiotherapy and Clinical Oncology (AIRO). Oral Oncol. 2021;115:105189.

28. He G, Liu S. Quality of life and coping styles in Chinese nasopharyngeal cancer patients after hospitalization. Cancer Nurs. 2005;28:179–186.

29. Lin CC, Chang AP, Cleeland CS, Mendoza TR, Wang XS. Taiwanese version of the M. D. Anderson symptom inventory: symptom assessment in cancer patients. J Pain Symptom Manag. 2007;33:180–188.

30. Mystakidou K, Cleeland C, Tsilika E, Katsouda E, Primikiri A, Parpa E, et al. Greek M.D. Anderson Symptom Inventory: validation and utility in cancer patients. Oncology. 2004;67:203–210.

31. Tseng TH, Cleeland CS, Wang XS, Lin CC. Assessing cancer symptoms in adolescents with cancer using the Taiwanese version of the M. D. Anderson Symptom Inventory. Cancer Nurs. 2008;31:E9–E16.

32. Polit DF, Beck CT. Nursing Research: Generating and Assessing Evidence for Nursing Practice. 9th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.

33. Cohen JW. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Lawrence Erlbaum Associates; 1988.

34. Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models: tests of significance and descriptive goodness-of-fit measures. Methods Psychol Res. 2003;8:23–74.

35. Pallant J. SPSS Survival Manual: A Step by Step Guide to Data Analysis Using IBM SPSS. 5th ed. Allen & Unwin; 2013.

36. DeVellis RF. Scale Development: Theory and Applications. 2nd ed. Sage; 2003.

37. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to their Development and Use. 4th ed. Oxford University Press; 2008.

38. Fleiss JL. Reliability of measurement. In: Fleiss JL, ed. The Design and Analysis of Clinical Experiments. New York: John Wiley & Sons; 1986:1–32.

39. Chow KM, Chan CW, Chan JC, Choi KK, Siu KY. A feasibility study of a psychoeducational intervention program for gynecological cancer patients. Eur J Oncol Nurs. 2014;18:385–392.

40. Gu C, Chan CW, He GP, Choi KC, Yang SB. Chinese women’s motivation to receive future screening: the role of social-demographic factors, knowledge and risk perception of cervical cancer. Eur J Oncol Nurs. 2013;17:154–161.

41. Chan CW, Choi KC, Chien WT, Cheng KK, Goggins W, So WK, et al. Health-related quality-of-life and psychological distress of young adult survivors of childhood cancer in Hong Kong. Psycho Oncol. 2014;23:229–236.